Cresco Labs (OTCMKTS:CRLBF – Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $172.10 million for the quarter.
Cresco Labs Stock Performance
Shares of CRLBF stock opened at $0.76 on Monday. The company has a market capitalization of $371.57 million, a P/E ratio of -3.81 and a beta of 1.79. Cresco Labs has a fifty-two week low of $0.72 and a fifty-two week high of $2.60. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The stock has a 50 day moving average price of $0.91 and a two-hundred day moving average price of $1.23.
Analysts Set New Price Targets
CRLBF has been the subject of several analyst reports. Roth Capital raised shares of Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Cormark downgraded shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a research note on Monday, November 11th. Finally, Atb Cap Markets cut Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $2.50.
About Cresco Labs
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Read More
- Five stocks we like better than Cresco Labs
- With Risk Tolerance, One Size Does Not Fit All
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- When to Sell a Stock for Profit or Loss
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.
